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ABSTRACT Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory
disease and its prevalence is increasing worldwide, in both industrialised and developing countries. Its
prevalence is ∼5% in the general population and it is the fourth leading cause of death worldwide. COPD
is strongly associated with cardiovascular diseases; in fact, ∼64% of people suffering from COPD are
treated for a concomitant cardiovascular disease and approximately one in three COPD patients die as a
consequence of cardiovascular diseases.
Inhaled bronchodilators might have adverse cardiovascular effects, including ischaemic events and
arrhythmias, and beta-blockers might adversely influence the respiratory symptoms and the response to
bronchodilators. For these reasons, it is important to know the safety profiles and the possible interactions
between these two classes of drug, in order to prescribe them with greater awareness.
In this article, we review the literature about the epidemiology of COPD, its association with
cardiovascular diseases, and the safety of concurrent use of inhaled bronchodilators and beta-blockers, as a
tool for improving the approach to complex therapies in clinical practice.
Introduction
Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory disease, its
prevalence is increasing worldwide, and it is currently the fourth leading cause of death worldwide (third
in the USA) [1]. It results in a substantial waste of economic resources, in particular from dealing with
exacerbations and hospitalisations [2, 3]. COPD is becoming more widespread in both industrialised and
developing countries, with its prevalence reaching ∼5% in Western countries. In particular, in patients
aged >65 years, prevalence is estimated to be >10% [1]. According to the multicentric REPOSI (Registro
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Politerapie SIMI) study (a collaborative registry of polypathologies in Italy), which involved elderly patients
admitted to internal medicine wards, the prevalence was >24% in men and 16% in women [3].
It is important to note that the prevalence of COPD has increased in women in recent decades. Although
this could be explained by increased tobacco use, it has been suggested that, for the same degree of
tobacco exposure, women may be more susceptible than men to smoking-induced lung injury, due to a
peculiar bronchial immunoreactivity [4, 5]. COPD is also strongly associated with cardiovascular diseases.
In fact, ∼64% of people suffering from COPD are treated for a concomitant cardiovascular disease [6], and
about one third of COPD patients die because of cardiovascular diseases [7].
Because inhaled bronchodilators cause adverse cardiovascular effects, including ischaemic events and
arrhythmias, and beta-blockers could adversely influence respiratory symptoms and the response to
bronchodilators, it is important to know the safety profiles and the possible interactions between these two
classes of drug, in order to use them with greater awareness.
COPD and cardiovascular comorbidities
In the last few years, awareness of the systemic nature of COPD and about the comorbidities that
contribute to its severity and mortality has grown [6]. In particular, there is a strong association among
COPD, heart failure and ischaemic heart disease [2]. Other data from the literature point out that patients
with COPD are at an increased risk of developing ischaemic heart disease and myocardial infarction than
patients without COPD [7, 8]. Moreover, 17% of patients with myocardial infarction suffer from COPD.
The prevalence of COPD in patients with heart failure ranges from 20% to 32% of cases, and the
prevalence of heart failure in COPD patients is >20% [9]. Data from the REPOSI registry indicate a
prevalence of heart failure close to 30% in COPD patients aged >65 years with comorbidities [3].
The association between COPD and cardiovascular diseases varies according to different COPD
phenotypes [10]. In particular, individuals with chronic bronchitis and frequent exacerbations experience
more cardiovascular events (arrhythmias, myocardial infarction and heart failure) than those without
exacerbations, probably because of an underlying inflammatory–hypoxic state, but also because it is not
easy to distinguish between COPD exacerbations and both ischaemia and heart failure. Conversely, the
emphysematous phenotype shows a stronger association with diastolic dysfunction due to lung
hyperinflation, which adversely influences ventricular filling and cardiac output.
Due to increasing life expectancy and to improvements in both diagnostic and therapeutic tools, this
coexistence of diseases will increase inexorably in the future. In evidence of this, a high proportion of
patients with COPD (∼80%) are on multiple drugs, not only for respiratory and cardiovascular conditions
[6]. The β2-agonists and anticholinergics used for the treatment of COPD have adverse cardiovascular
effects, including ischaemic events and arrhythmias, and beta-blockers can adversely influence respiratory
symptoms and the response to bronchodilators; therefore, it is clear how difficult it is to determine the
approach and management of patients with COPD and cardiovascular comorbidities.
The concomitant presence of COPD and cardiopathy results in a greater severity of the clinical condition.
Both conditions share similarities such as the age of the population affected, and both have a common risk
factor in smoking, which is closely related to COPD and ischaemic heart disease and is the leading cause
of heart failure in Western countries [11]. COPD also determines an increased risk of cardiovascular
disease, including ischaemic heart disease and heart failure, because of the latent chronic organ-specific
and systemic inflammatory state [9, 12]. Thus, the presence of these comorbidities might adversely affect
the prognosis.
Beta-blockers in COPD and cardiovascular comorbidities
Poor prognosis in patients with heart failure and COPD is probably due to several factors, including
interactions of the two conditions, diagnostic delay and the often unjustified rejection of the use of
beta-blockers, which are essential for the treatment of ischaemic heart disease and heart failure. The
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not discourage their use
[13]. In fact, according to all heart failure guidelines, once it has been established that there are no other
contraindications, beta-blocker therapy is mandatory.
In this regard, a meta-analysis from 2012 pointed out that cardioselective beta-blocker use in COPD
patients is safe and has a protective effect on all-cause mortality [14]. Consistent with this, an earlier
Cochrane review in 2005 had already analysed the available data on the use of β1-selective beta-blockers in
COPD patients and concluded that, following administration of a β1-selective beta-blocker, there was no
evidence of adverse effects on respiratory function. More importantly, these beta-blockers did not
adversely affect the effects of routinely inhaled β2-agonists on bronchial smooth muscle [15]. Several
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studies have demonstrated improved outcomes or a good safety profile (table 1). In particular, a cohort
study using a database provided by National Health Service Scotland (Tayside Allergy and Respiratory
Disease Information System (TARDIS)) evaluated 5977 patients aged >50 years, with a mean follow-up of
4.35 years [16]. Beta-blockers were cardioselective in 88% of cases, and their administration resulted in a
reduction of 22% in all-cause mortality when added to established inhaled stepwise therapy, regardless of
COPD severity. Furthermore, patients treated with beta-blockers reduced oral corticosteroid use and
hospital admissions due to respiratory disease.
It has also been reported that, in COPD patients with ischaemic heart disease, heart failure and
hypertension, beta-blocker use significantly reduces 1-year mortality and hospital admissions due to
respiratory disease, compared to patients not treated with beta-blockers [2]. Moreover, it has been shown
that cardioselective beta-blockers are undoubtedly better than non-selective beta-blockers. Consequently,
there is no valid reason to avoid the use of β1-selective beta-blockers in individuals with COPD and
concomitant cardiac disease.
Table 2 shows the classification of the most common beta-blockers according to both selective and
non-selective properties. The β1-selective beta-blockers are also classified according to intrinsic
sympathetic activity, the importance of which is discussed later in this section.
Although beta-blockers are the mainstay of treatment in patients with ischaemic heart disease and COPD,
in these patients the use of inhaled long-acting β-agonists (LABAs) and inhaled long-acting muscarinic
receptor antagonists (LAMAs) is more complex and still a matter of controversy. In this regard, a
retrospective cohort study involving 220 elderly patients (mean±SD age 84.1±6.9 years) diagnosed with
COPD was recently conducted [17]. The patients were divided into four groups by the use of
beta-blockers, LABAs, combination therapy (LABA plus beta-blocker) and controls. N-terminal pro-brain
natriuretic peptide and left ventricular ejection fraction were measured and evaluated. Over the follow-up
period (>20 months), there was no significant difference in all-cause mortality among the four groups of
treatment.
These data would indicate that there is no association between the use of LABAs, beta-blockers or
combination therapy with cardiac function and all-cause mortality in elderly COPD patients, which means
that they could be prescribed in a relatively safe manner in this population. The benefits associated with
TABLE 1 Characteristics of the studies using beta-blockers in patients with chronic obstructive pulmonary disease (COPD) and
cardiovascular comorbidities
First author [ref.] Year Design Population Safety outcome
SALPETER [15] 2005 Review of data from 22
randomised, blinded controlled
trials
1567 patients with COPD No adverse effect of cardioselective
beta-blockers on lung function or
respiratory symptoms compared to
placebo
SHORT [16] 2011 Retrospective cohort study
using a disease-specific
database of COPD patients
(TARDIS)
5977 patients aged >50 years
with COPD
Reductions in mortality, exacerbations and
hospital admissions; additive benefits with
inhaled therapy; 88% of beta-blockers
used were cardioselective
ETMINAN [14] 2012 Systematic review and
meta-analysis of nine
retrospective cohort studies
99877 patients with COPD Protective effect of beta-blockers
(selective and non-selective) with respect
to all-cause mortality
STEFAN [2] 2012 Retrospective cohort study 35082 patients aged >40 years with
COPD and coexistent ischaemic
heart disease, chronic heart failure
or hypertension
β1-selective beta-blocker therapy among
chronic users appears to be safe during a
hospitalisation for acute COPD
exacerbation; β1-selective beta-blockers
are superior to non-selective
beta-blockers in this category of patients
ZENG [17] 2013 Retrospective cohort study 220 elderly male COPD patients
(mean±SD age 84.1±6.9 years)
No association between the use of
β2-agonists, beta-blockers or
beta-blocker/β2-agonist combination
therapy with cardiac function and
all-cause mortality in elderly male COPD
patients
TARDIS: Tayside Allergy and Respiratory Disease Information System.
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beta-blocker treatment could be due to the reduction of cardiac frequency and the prevention of
arrhythmogenesis induced by excessive use of bronchodilators during exacerbations and, in general, to the
control of the deleterious effects of systemic sympathetic activation. Moreover, the improved cardiac
haemodynamics due to the treatment could also have benefits on lung function, increasing exercise
tolerance and preventing or mitigating chronic pulmonary hypertension [18].
Another important issue is that asthma and COPD may coexist in the same individual, leading to a
condition that has been termed asthma–COPD overlap syndrome (ACOS). Ageing is associated with the
coexistence of the two diseases. CASTIGLIA et al. [19] extensively reviewed this issue and raised some
speculative and interesting observations. Additionally, a meta-analysis investigated the effect of
cardioselective beta-blockers on the respiratory function of patients with “reactive” airway disease, defined
by the authors as asthma or COPD with a reversible obstructive component [20]. This definition probably
includes those patients who would nowadays be defined as having ACOS. In particular, the findings of this
meta-analysis underscored that the use of β1-blockers is safe with regard to pulmonary function and
respiratory symptoms, and is not associated with increased use of inhaled β2-agonists. Moreover, among
β1-selective beta-blockers, those without intrinsic sympathetic activity cause a lower forced expiratory
volume in 1 s (FEV1) reduction than the other categories of beta-blocker, which can be noted after the
first administration [20]. Furthermore, they appear to cause an upregulation and sensitisation of
β2-receptors, resulting in an increased response to exogenous β2-agonists. In patients treated with LABA
plus beta-blocker without intrinsic sympathetic activity, FEV1 increased by 12% compared to those treated
with placebo, while those treated with LABA plus beta-blocker with intrinsic sympathetic activity did not
show any improvement in FEV1 [20].
The correct use of β1-selective blockers, in particular without intrinsic sympathetic activity, is an example
of good clinical practice in patients with mild-to-moderate COPD and associated heart failure and/or
coronary artery disease. Moreover, bisoprolol reduced the incidence of heart failure and/or COPD
exacerbation compared with carvedilol in a retrospective longitudinal analysis [21]. Although there is a
high tolerance of β1-selective blockers and certain benefits in cardioprotection, their prescription should
always be preceded by a careful evaluation of each patient’s characteristics, and follow a proper and safe
drug dosage.
LABAs and LAMAs in COPD
LABAs and LAMAs, alone or in combination therapy, represent one of the mainstays of COPD treatment.
However, these drugs do not only bind lung receptors. In fact, β2-agonists bind the β2-receptors of the
respiratory system with more affinity, and β1-receptors of the heart with less affinity. β2-agonists, acting on
the sinus node, increase the heart rate and, acting on the myocardium, increase stroke volume, thus
exerting their sympathomimetic effect. Antimuscarinic agents may bind M2 receptors of the sinus node,
potentially increasing the heart rate and, consequently, the myocardial oxygen consumption. Thus, their
effect should be considered in the therapy management of patients with concomitant heart disease. Several
studies have been conducted to clarify the extrapulmonary effects of LABAs and/or LAMAs, mainly
focusing on their use in patients with cardiac comorbidities (table 3).
A 2015 meta-analysis, conducted to assess the safety profile of LABAs and LAMAs for severe arrhythmias
(including atrial fibrillation and other tachyarrhythmias), showed no statistically significant differences
TABLE 2 Classification of the most common beta-blockers according to selective and
non-selective properties
Non-selective β1-selective
β1- and β2-blockers α- and β-blockers ISA− ISA+
Propranolol
40–280 mg twice daily
Labetalol
200 mg twice daily
Atenolol
25–100 mg once or twice daily
Nebivolol
5–10 mg once daily
Sotalol
80–160 mg twice daily
Carvedilol
12.5–50 mg twice daily
Metoprolol




40–320 mg once daily
Bisoprolol
2.5–10 mg once daily
Esmolol
50–200 μg·kg−1·min−1
Data are presented as usual dosage in clinical practice. ISA: intrinsic sympathetic activity.
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among all the agents [22]. Salmeterol showed a lower cardiovascular mortality risk versus placebo and
tiotropium (Respimat Soft Mist Inhaler; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany).
Tiotropium was associated with higher cardiovascular mortality risk. However, in another context,
tiotropium was shown to be more effective in reducing exacerbations than salmeterol and indacaterol,
regardless of association with inhaled corticosteroids [27, 28]. Moreover, the UPLIFT study
(Understanding Potential Long-term Impacts on Function with Tiotropium), a double-blind, randomised,
placebo-controlled clinical trial conducted on >6000 patients (followed up for 4 years), revealed a reduced
acute myocardial infarction and cardiovascular mortality incidence versus placebo [29]. Thus, tiotropium is
considered the gold standard drug as monotherapy. The TIOSPIR study (TIOtropium Safety and
Performance In Respimat) also showed that different formulations of tiotropium (Respimat at a dose of 2.5
or 5 μg and HandiHaler at 18 μg; both from Boehringer Ingelheim GmbH) had a similar risk of death
[30]. Furthermore, the risk of exacerbation and major adverse cardiovascular events did not differ
significantly among the three treatment groups [30], or upon switching patients from tiotropium
HandiHaler to tiotropium Respimat [31].
Current evidence supports the safety of aclidinium [32] and glycopyrronium [33, 34], with no substantial
differences with other LAMAs.
The aforementioned 2015 meta-analysis revealed no significant differences in cardiovascular safety profile
between combination therapy with LAMA plus LABA and monotherapy [22]. Several reviews and
meta-analyses assessing the effectiveness and safety of LAMAs and LABAs in COPD patients have
demonstrated that dual bronchodilation is effective and safe, with no increase in adverse events when
compared with monotherapies [24, 25, 35]. Moreover, the FLAME study (which studied the effect of
indacaterol–glycopyrronium versus salmeterol–fluticasone on COPD exacerbations) showed no evidence of
significant cardiovascular death or cardiac pump failure, supporting a good safety profile of the LABA
(indacaterol)/LAMA (glycopyrronium) association [36].
Unfortunately, these studies often involve a selected patient population. Since patients with COPD and
other significant comorbidities are not included in these studies [24], these pieces of evidence may not
reflect real-life clinical scenarios.
TABLE 3 Characteristics of studies using long-acting β-agonists (LABAs) and/or long-acting muscarinic receptor antagonists
(LAMAs) in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular comorbidities
First author [ref.] Year Design Population Safety outcome
TRICCO [22] 2015 Systematic review and network
meta-analysis of 208 randomised
clinical trials
134692 adults with COPD No statistically significant differences in
risks of serious arrhythmia across any of
the compared agents
TASHKIN [23] 2015 Post hoc analysis of all-cause
mortality and serious cardiac
adverse events using data from the
UPLIFT study
6562 patients with COPD with
recent myocardial infarction,
heart failure or unstable
rhythm disorder
Risk of cardiac events, mortality or SAEs
was not increased by tiotropium versus
placebo in patients experiencing cardiac
events
OBA [24] 2016 Systematic review and network
meta-analysis of 23 trials
27172 patients older than 35
or 40 years with a diagnosis
of COPD
Combination therapy had similar effects on
safety outcomes, including mortality, total
SAEs, cardiac SAEs and dropouts,
compared with monotherapy
CALZETTA [25] 2016 Systematic review and
meta-analysis of 22 randomised
clinical trials
23168 with a diagnosis of
COPD
No evidence of any significant difference
concerning the cardiac safety profile of
combination therapy compared with
monocomponents
LAHOUSSE [26] 2016 Review of 93 studies about cardiac
safety of bronchodilatator therapy
in COPD
>700000 patients with a
diagnosis of COPD
LAMAs and/or LABAs are safe when used
in the appropriate dose in adherent
patients with COPD without uncontrolled
cardiovascular disease or other notable
comorbidities; cardiac safety is less
evident when used inappropriately (e.g.
overdosing) or in patients with COPD and
substantial cardiovascular disease,
prolonged QTc interval or polypharmacy
UPLIFT: Understanding Potential Long-term Impacts on Function with Tiotropium; SAEs: severe adverse effects.
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It is possible to infer that a LAMA or LABA alone, or in combination therapy, are safe if proper doses are
administered in compliant patients with COPD, well-controlled cardiovascular diseases and no other
relevant comorbidities. However, LAMA and LABA cardiovascular safety is reduced if they are not used
correctly (i.e. overdose) or are used in patients with COPD and other significant cardiovascular diseases,
QTc interval prolongation or who are on multiple drugs [24]. Therefore, they should be used with caution
in these categories of patient.
Conclusions
This review shows that, although cardioselective beta-blockers may be used more extensively and properly
in COPD patients with cardiovascular comorbidities, bronchodilators should be used with more caution in
a particular subset of patients with cardiovascular comorbidities. Further pragmatic real-world-based
clinical trials are required to assess the safety of these classes of drugs in COPD patients with
cardiovascular comorbidities.
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